||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Sinclair Pharma Share Discussion Threads
Showing 1576 to 1598 of 1600 messages
|Well done QS.
My betting is you are feeling grumpy because you wish you had bought more - invested your entire savings.
Such is the way with Aim investments.
Still I grant you the fact that you got it right!|
|It is ABZA. Top mover today.
|U got the wrong ticker BTW
Had a scan through, really no idea what they do, so significance of this mornings' news lost on me I'm afraid, just a few large numbers being thrown about.....|
|having held SPH, thought I would point out ABZ's RNS this morning....going bonkers as very tightly held...interesting though...GLA|
|I imagine that Tosca fund will start throwing their weight around eventually!|
|Since the disposal/subsequent interest in the aesthetics side you can be sure that there are one or two companies closely following the trials and tribulations here. Gotta wonder whether recent fx movements coupled with progress to date could focus attention once again....I question the rationale of SPH remaining an independent entity going fwd with such a ltd portfolio....acquire or be acquired?|
|'two consecutive days' ?????
It's the stockmarket, rational behaviour to be found elsewhere...
|Good post `egg` my sentiments also.|
|Welcome to Aim.
Gut feeling and many years experience of this is that if the price drops on good news the chances of it going up are increased, plus Sod's law says if you sell they are bound to go up!
Face it, the company is sound, messrs Soros and Tosca fund are in there big time and chances are that they know more than your average PI.|
|Why is the price dropping on two consecutive days? Trading update was positive was it not? Am I missing something?|
|Nothing we didn't know but
|Doubt this liquidity will be maintained too...|
|Wouldn't and never buy for the takeover.
That said this is looking a very clean, focussed business.|
|The figures are actually pretty much in line with expectations and that's being reflected in the price reaction.(Can't say I like share buy backs,Studies have shown that the ultimate benefits to shareholders are negligible.If they haven't enough to do using cash flow to build the business,they can always pay a dividend.)The stock won't appear glaringly cheap until it turns a bottom line profit.Given the time that we've waited for the company to make money,the market is unlikely to take anything for granted.Once it does turn a profit,then bid rumours will probably start to circulate.The stock is a good hold but not screamingly cheap in my book.|
|Article in the Daily Mail yesterday about thread sutures being used to take the wrinkles out of womens' knees.
Doesn't say if they used Silhouette but the Harley Street clinic doing the proceedure do advertise it on their website.|
|Yes indeed, I feel we have a little gem here the trading statement is very encouraging. The restructured Company is very young with great potential, IMHO would like to see a share buy back in the future.|
|I think the shares are a straight Buy on that statement.. 60p is my target..|
|Yep, pleased with that though can't ignore favourable fx
Hardman & Co @HardmanandCo 17m17 minutes ago
$SPH Underlying sales +37% in 2016 exceed demanding targets set by #SinclairPharma. Full results 21st March. http://www.investegate.co.uk/sinclair-pharma-plc--sph-/rns/pre-close-trading-update/201701170700062924U/ …
0 replies . 0 retweets 0 likes|
|This was the 2016 half yearly report.I think that reported full year sales growth of 37% has fallen slightly short of interim expectations.Lets see how the market reacts.
"On track to meet guidance of 40% sales growth for calendar year 2016, pre Brazil consolidation and US Silhouette Soft(R) sales".21 Sept 2016|
|That's the face lift I needed!|
|Sales for the twelve months ended 31 December 2016 were GBP37.8 million, (GBP34.3 million at constant currency) compared to pro forma sales for the aesthetics business of GBP25.0 million for the same period in 2015, representing headline growth of 51%. Underlying sales growth, excluding Silhouette Instalift(TM) US sales, Brazilian sales and currency tailwinds was 37%.Good figures.Steady as she goes.Statement references that company has undertaken currency hedging in the latter paragraph.|
|Well, buyer(s) and seller(s) pitched head to head today.....|